(Alliance News) - Johnson & Johnson on Friday announced that ustekinumab, a treatment for ulcerative colitis, saw a 55% rate of remission after a Phase 3 study. The New Jersey, US-based pharmaceutical major announced new three-year data from the long-term extension of the Stelara drug, or ustekinumab, Phase 3 UNIFI study.
Greg Roxburgh
- Head Writer, Diplomatic Network (ASIA)
London
Photojournalist and writer. South African. Yes man.
Get in touch with Greg
Contact Greg, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck RackActions
Greg Roxburgh’s Biography
Read Full Bio →Photographer and writer. Yes man.
Interview
See all 4 answers →Who's your favorite fictional journalist?
Why choose a fictional journalist when there are so many amaaazing real journalists? I have so many I can't even count them.
Who do you wish followed you?
My mum but she's a bit technologically challenged.
What's your favorite drink?
Love a bez.